CSD melanomas exhibit higher mutational burdens dominated by UV signature mutations (C→T transitions), frequent activating mutations in NRAS and NF1 and the inactivation of tumor suppressors such as CDKN2A and TP53. These tumors typically develop through a gradual progression model from precursor lesions. The gene discussed is CDKN2A; the disease is melanoma.